Research and Markets: Examine Bioanalysis in Cancer Research as 12 Million Cancer Deaths Are Predicted for 2030

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/698dea/bioanalysis_in_can) has announced the addition of Future Science Ltd's new report "Bioanalysis in Cancer Research" to their offering.

Statistics from the World Health Organization show cancer to be a leading cause of death worldwide, with 7.4 million deaths (-13% of all deaths worldwide) attributed to cancer in 2004. This rate is predicted to continue growing, with an estimated 12 million cancer deaths predicted for 2030. Tumors arise from a single normal cell and are caused by interactions between genetic factors and exposure to any of the following: physical (e.g. UV or radiation), chemical (e.g. asbestos or tobacco) and biological (e.g. hepatitis B or Human Papilloma Virus) carcinogens.

Many cancer deaths could be prevented by avoiding risk factors, for example by stopping smoking or losing weight. Survival outcomes can be significantly improved by early diagnosis, appropriate disease monitoring and disease management.

Bioanalysis has a pivotal role in cancer diagnosis and prognosis, determining the appropriate therapy and, subsequently, monitoring the effectiveness of the therapy. Important topics such as quantification of diagnostic and prognostic biomarkers, genomics for determining the appropriate therapy for particular patients and the role of therapeutic drug monitoring in chemotherapy management are discussed by international experts in this special focus issue of Bioanalysis.

Key Topics Covered:

EDITORIAL:

  • Steps along the road to electrochemical devices for early cancer diagnosis

COMMENTARY:

  • Cancer-related forecast biomarkers: a topic in focus of the Worldwide Innovative Network in Personalized Cancer Medicine (WIN)

REVIEWS:

  • Derivation of cancer diagnostic and prognostic signatures from gene expression data
  • Therapeutic drug monitoring in cancer chemotherapy
  • Biomarkers in cancer micrometastasis: where are we at?
  • miRNAs as biomarkers in colorectal cancer diagnosis and prognosis
  • Aptamers selected by cell-SELEX for application in cancer studies

For more information visit http://www.researchandmarkets.com/research/698dea/bioanalysis_in_can



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.